Patents Assigned to Sterna Biologicals GmbH & Co. KG
-
Publication number: 20210299041Abstract: The invention relates to the use of an aerosol-generating device for generating an aerosol of a composition, for administering the composition by inhalation, wherein the composition comprises at least one antisense-molecule. The aerosol-generating device has a membrane having a perforation, wherein the composition for generating the aerosol is brought into contact with the membrane, and the membrane of the aerosol-generating device are caused to vibrate. The perforation is formed of at least one group of passage openings, wherein each passage opening of a group has a diameter of at least 3 ?m and at most 5 ?m at the narrowest point of the passage opening, and wherein the at least one group of passage openings comprises at maximum 500 passage openings per mm 2 of the membrane.Type: ApplicationFiled: July 29, 2019Publication date: September 30, 2021Applicant: Sterna Biologicals GmbH & Co. KGInventor: Jonas Renz
-
Publication number: 20210177883Abstract: The invention relates to a composition for treating a patient suffering from an intestinal condition associated with chronic inflammation, wherein the composition comprises at least one DNAzyme which specifically inhibits the expression of GATA-3. A further aspect of the invention relates to the use of such a composition as drug.Type: ApplicationFiled: January 15, 2019Publication date: June 17, 2021Applicant: STERNA BIOLOGICALS GMBH & CO. KGInventor: Jonas Renz
-
Publication number: 20210161939Abstract: The invention relates to a composition for treating a patient suffering from a respiratory tract disease associated with chronic inflammations, the composition comprising at least one DNAzyme which specifically downregulates the expression of GATA-3 and/or comprising at least one DNAzyme which specifically downregulates the expression of Tbet. The composition is characterized in that the concentration of the DNAzyme in the composition is lower than 75 mg/ml. The invention also relates to a method for producing the composition according to the invention and to the use of the composition drug for treating a patient suffering from a respiratory tract disease associated with chronic inflammations.Type: ApplicationFiled: December 20, 2018Publication date: June 3, 2021Applicant: STERNA BIOLOGICALS GMBH & CO. KGInventor: Jonas Renz
-
Patent number: 10591489Abstract: Chronic inflammation is an increasing medical problem area of high socioeconomic significance. The invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation, and to a medicament for treating such a patient. To that end, the gene expression of GATA-3 and/or Tbet in a biological isolate of the patient is measured and used for association with a molecular phenotype of the illness.Type: GrantFiled: October 12, 2017Date of Patent: March 17, 2020Assignee: STERNA BIOLOGICALS GMBH & CO. KGInventors: Agnieszka Turowska, Joachim Bille
-
Patent number: 10487325Abstract: The invention relates to GATA-3 inhibitors for use in the treatment of Th2-driven asthma, in particular to DNAzymes directed at GATA-3 for use in the treatment of a patient suffering from allergic asthma, wherein the patient is characterized by (i) a blood eosinophil count of 3% or more, particularly of 4% or more, more particularly of 5% or more; and/or (ii) blood eosinophil count of 350×106/L or more, particularly of 450×106/L or more; and/or (iii) fractional expiratory nitric oxide of 40 ppb or more.Type: GrantFiled: May 12, 2016Date of Patent: November 26, 2019Assignee: STERNA BIOLOGICALS GMBH & CO. KGInventors: Joachim Bille, Jonas Renz
-
Patent number: 9791454Abstract: Chronic inflammation is an increasing medical problem area of high socioeconomic significance. The invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation, and to a medicament for treating such a patient. To that end, the gene expression of GATA-3 and/or Tbet in a biological isolate of the patient is measured and used for association with a molecular phenotype of the illness.Type: GrantFiled: September 4, 2013Date of Patent: October 17, 2017Assignee: STERNA BIOLOGICALS GMBH & CO. KGInventors: Agnieszka Turowska, Joachim Bille
-
Patent number: 9404110Abstract: The invention relates to a cosmetic and/or dermatological and/or pharmaceutical composition for the topical use and application of oligonucleotides, in particular antisense-oligonucleotides such as DNAzyme, siRNSs, asDNAs or ribozymes for use as an agent against inflammatory diseases by means of emulsions having a dispersed, internal, discontinous aqueous phase.Type: GrantFiled: December 10, 2015Date of Patent: August 2, 2016Assignee: STERNA BIOLOGICALS GMBH & CO. KGInventors: Thomas Schmidts, Holger Garn, Frank Runkel
-
Patent number: 9249413Abstract: The invention relates to a cosmetic and/or dermatological and/or pharmaceutical composition for the topical use and application of oligonucleotides, in particular antisense-oligonucleotides such as DNAzyme, siRNAs, asDNAs or ribozymes for use as an agent against inflammatory diseases by means of emulsions having a dispersed, internal, discontinuous aqueous phase.Type: GrantFiled: February 11, 2011Date of Patent: February 2, 2016Assignee: STERNA BIOLOGICALS GMBH & CO. KGInventors: Thomas Schmidts, Holger Garn, Frank Runkel
-
Publication number: 20140248377Abstract: The invention relates to a multiple emulsion for the application of at least one pharmaceutical or cosmetic active ingredient which has an external water phase W1, an oil phase O dispersed in the external water phase W1 and an internal water phase W2 dispersed in the oil phase O, where, in the internal water phase W2, at least one electrolyte selected from the group of the alkali metal and alkaline earth metal halides and sulphates and at least one hydrophilic active ingredient is provided. In order to achieve a high stability of the emulsion, the invention envisages that the external water phase comprises a hydrophilic emulsifier which is a polymer of ethylene oxide and propylene oxide, and that the oil phase O is formed by triacylglycerides and has a lipophilic emulsifier from the group of dimethicones.Type: ApplicationFiled: August 2, 2012Publication date: September 4, 2014Applicant: STERNA BIOLOGICALS GMBH & CO. KG BIOMEDIZINISCHES FORSCHUNGSZENTRUMInventors: Frank Runkel, Thomas Schmidts
-
Patent number: 8247544Abstract: A DNAzyme is disclosed, which comprises: (i) a catalytic domain with a nucleotide sequence GGCTAGCTACAACGA or a modified sequence of comparable biological effect, which cleaves T-bet mRNA at every purine-pyrimidine binding site to which it is bound; (ii) a right substrate binding domain which is contiguous with the 3?-end of the catalytic domain; and (iii) a left substrate binding domain which is contiguous with the 5?-end of the catalytic domain, whereby the two substrate binding domains are respectively complementary to two regions of the T-bet mRNA so that they hybridize with the mRNA; are active in vivo; and contain the sequences td 69 GGCAATGAA GGC TAGCTACAACGA TGGGTTTCT or td70 TCACGGCAA GGCTAGCTACAACGA GAACTGGGT.Type: GrantFiled: March 1, 2011Date of Patent: August 21, 2012Assignee: Sterna Biologicals GmbH & Co. KGInventors: Serdar Sel, Harald Renz
-
Patent number: 8119789Abstract: The present invention relates to a method for producing of a cell and/or tissue and/or disease phase specific medicament against against chronic inflammatory diseases. Disease, cell type, tissue and/or stage specific proteins and nucleic acids are identified with regard to their modified expression pattern and the corresponding nucleic acids are analyzed as possible attack targets for DNAzymes or siRNA. What follows is a design of active specific DNAzymes and siRNA which bind to the target sequence and cleave it such that a medicament against chronic inflammatory diseases and autoimmune diseases is provided.Type: GrantFiled: October 1, 2004Date of Patent: February 21, 2012Assignee: Sterna Biologicals GmbH & Co. KGInventors: Serdar Sel, Harald Renz